Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Founded in 2018, the company's mission is to transform treatment paradigms by creating scalable, affordable, and off-the-shelf cell therapies.

The company's core technology involves engineering induced pluripotent stem cells (iPSCs) and differentiating them into induced mesenchymal stem cells (iMSCs). These allogeneic synthetic iMSCs are designed to provide a scalable, off-the-shelf treatment solution, eliminating the need for patient-specific cell harvesting. Ernexa's pipeline includes ERNA-101, a lead cell therapy product aimed at activating the immune system to combat cancer cells, with an initial focus on platinum-resistant ovarian cancer. Additionally, ERNA-201 is being developed to target inflammation and treat autoimmune diseases such as rheumatoid arthritis.

Sanjeev Luther serves as the President and CEO of Ernexa Therapeutics. The company, which was formerly known as Eterna Therapeutics Inc. and underwent a name change in March 2025 to reflect its sharpened strategic focus, is publicly traded on Nasdaq under the ticker symbol ERNA. In April 2026, Ernexa Therapeutics announced a 1-for-25 reverse stock split, effective May 4, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company is advancing towards first-in-human clinical trials in 2026, following a successful Pre-IND meeting with the U.S. FDA for ERNA-101 in ovarian cancer.